The future of human longevity: new approaches to healthcare and cancer

The future of human longevity: new approaches to healthcare and cancer

20 Sep 2012

Location: Singapore-ETH Centre (SEC), Singapore

About the event

Swiss Re, one of the world’s largest re/insurers, in collaboration with swissnex Singapore, one of five Swiss science and technology consulates worldwide, cordially invite you to this interactive half-day conference, to be held at the Future Cities Laboratory at the Singapore-ETH Centre (SEC) in Singapore.

Objective

Thirty years ago, the actuarial tables did not predict we would live this long. That has repercussions, particularly when combined with a low birth rate. Swiss Re is seeking to improve understanding of future longevity trends. As such, we will be addressing two major influences on the length of life:

  • Effective healthcare has clear benefits for the extension of life. Leading experts will focus on the provision of health care, its implementation and covering its cost
  • Cancer is one of the leading causes of death in Asia. We will discuss some of the latest developments in cancer research, from cost-effectiveness, genealogical and epidemiological perspectives

Target audience

Swiss Re insurance industry clients heading mortality and longevity research / pricing unit, and leading experts in fields spanning epidemiology, the aging process, and cutting edge advances in the prevention, detection and treatment of disease.


Note: This event may be photographed, filmed and /or recorded. A summary of the event, pictures and/or a video of the event in which you may appear may be posted and made available on Swiss Re’s and swissnex Singapore's internal and external websites and in printed materials.

Agenda

Thursday, 20 September 2012

Time difference compared to Central European Time: -6 hours

2:30pm

Welcome coffee and registration

3:00pm

Welcome
Suzanne Hraba-Renevey, Director, swissnex Singapore
Christopher Lee, Head Client Markets Life & Health, Swiss Re

3:10pm

The impact behaviour has on the prevalence of cancer
John Schoonbee, Chief Medical Officer, Swiss Re

3:40pm

From health policy to implementation into clinical practice
David Matchar, Inaugural Director and Professor, Program in Health Services and Systems Research, Duke-NUS

4:10pm

Coffee break

4:40pm

Cost-effectiveness in cancer care
Helen Chung, Head of Health Policy Research, Swiss Re

5:00pm

Personalised medicine - novel cancer diagnostics and treatment
Christoph Nabholz, Head Business Development, Swiss Re Centre for Global Dialogue

5:20pm

Cancer in Asia
CHIA Kee Seng, Professor and Dean of Saw Swee Hock School of Public Health, National University of Singapore and Director, Centre for Molecular Epidemiology; Adjunct Professor of Epidemiology, Karolinska Institutet, Sweden

5:50pm

Closing remarks
Christopher Lee, Head Client Markets Life & Health, Swiss Re

6:00pm

Networking reception

7:00pm

Closing

Speakers

Kee-Seng Chia

CHIA Kee Seng

Dean and Professor, Saw Swee Hock School of Public Health; Director, NUS-GIS Center for Molecular Epidemiology


Read more
Helen Chung

Helen Chung

Head of Health Policy Research, Life & Health R&D, Swiss Re


Read more
David Matchar

David Matchar

Professor and Director, Health Services & Systems Research, Duke-NUS Graduate Medical School Singapore


Read more
Christoph Nabholz

Christoph Nabholz

Head Business Development, Swiss Re Centre for Global Dialogue


Read more
John Schoonbee

John Schoonbee

Chief Medical Officer, Swiss Re


Read more

Partners


Read more


Read more
SEC


Read more

Summary

Cancer has always been with us. As populations age and as lifestyle and behavioural factors impact our health, it is becoming increasingly common. Cancer is the largest single cause of death in many societies; and some believe that in future decades every second person in certain populations may suffer cancer. Despite billions spent on research, current standard treatments are only effective in a small percentage of patients. Tailored molecular treatments are more successful; but the medicine is in its infancy and, in a world of cost constrained health services, is very expensive.

All these factors will have a significant bearing on us and how long we live. That is of great interest to the re/insurance industry, which offers products covering life and health. Changes in longevity can have a significant impact on what the industry must charge in premiums and how much it reserves. Anticipating these changes help re/insurers and their customers prepare for tomorrow. Swiss Re, together with swissnex Singapore, organised the half-day cancer event to share knowledge of a disease which is establishing itself as the largest single determinant of global human health. Leading medical experts shared their specialist views on the current and likely future impact of cancer.

To read the entire summary, please click here.

From health policy to implementation into clinical practice

Cost-effectiveness in cancer care

Therapeutic nanomedicine – A critical review from the pharmaceutical industry perspective

The impact behaviour has on the prevalence of cancer

A mature market: Building a capital market for longevity risk

A liquid capital market in longevity risk can ensure long-term funding of people's longer lives.